What changes
Six things that are different when care generates evidence.
Real-world evidence, generated as you care.
Every clinical encounter the ILM touches becomes indexed, structured, and queryable. You don't extract data after the fact; you generate evidence prospectively, during routine care.
Publication-ready cohorts. Without the chart review.
Computable phenotyping and data lineage are built in from day one. The result: longitudinal patient cohorts that meet grant and journal standards, assembled automatically.
Consented cohorts. Governed by the institution.
Pharma collaborations run on the institution's terms, not through an intermediary who controls the data relationship. Consent, governance, and access are yours to define.
Grant-ready data lineage built in.
Every data point carries its provenance, who documented it, when, in what context. The lineage that grant reviewers and journals require is captured automatically.
No data broker. No egress. Yours.
Your research data never leaves your environment to be processed by a third party. The institution owns the evidence asset, not a vendor, not a platform.
Pharma engagement on your terms.
When you engage pharma partners, you come with structured, computable evidence assets, not raw data you have to prepare. You control the terms of any collaboration.
Data governance
Your data doesn't fund someone else's valuation.
Every data point, every cohort, every evidence asset generated through AIIM belongs to the institution. No broker relationship, no vendor lock-in, no hidden data sharing. Your research pipeline is yours, before, during, and after any engagement.